SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Dahl, S. G.
Right arrow Articles by Sylte, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dahl, S. G.
Right arrow Articles by Sylte, I.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

From genomics to drug targets

Svein G. Dahl

Ingebrigt Sylte

Department of Pharmacology, Institute of Medical Biology, University of Tromsø, Tromsø, Norway

The era of molecular biology and cloning brought new knowledge about the structure and function of drug receptors, and demonstrated that the term ‘receptor’ must be distinguished from other molecular drug targets such as enzymes, transporters and ion channels. Analysis of the targets of all current therapeutic drugs has shown that more than 95% of these are proteins.

The DNA sequencing of the entire human genome has led to identification of many previously unknown proteins that may represent potential drug targets. In order to understand fully the functional mechanisms of a protein, it is crucial to know its three-dimensional molecular structure. This may be determined experimentally by x-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy or electron microscopy, and computationally by structural bioinformatics and molecular modelling.

The molecular targets of nearly all current psychotropic drugs are membrane proteins. These have proven extremely difficult to purify and crystallize due to their amphipathic surface, with a hydrophobic area in contact with membrane phospholipids and polar surface areas in contact with the aqueous phases on both sides of the membrane.

We have used molecular modelling methods, based on crystal structures of related proteins, to model various neurotransmitter receptors and transporters. The receptor and transporter models have been used to study their structural properties, functional mechanisms and the molecular mechanisms of action of psychotropic drugs. Our results demonstrate the large structural flexibility of transporter and receptor proteins, with substantial movements and conformational changes taking place during substrate translocation in transporters, and by agonist induced receptor stimulation.

Key Words: receptors • transporters • molecular structure • molecular mechanisms • molecular dynamics

Journal of Psychopharmacology, Vol. 20, No. 4 suppl, 95-99 (2006)
DOI: 10.1177/1359786806066088


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




Advertisement